Literature DB >> 15681806

Neuroprotection from complement-mediated inflammatory damage.

Amod P Kulkarni1, Laurie A Kellaway, Debomoy K Lahiri, Girish J Kotwal.   

Abstract

Several neurodegenerative disorders, such as multiple sclerosis, Alzheimer's disease, and Parkinson's disease, are associated with inflammatory damage. The complex process of neuroinflammation involves various components of the immune system and the central nervous system. Particularly, brain astrocytes and microglial cells generate several inflammatory mediators like cytokines, leukotrienes, superoxide radicals, eicasonoids, and the components of the complement cascade. Complement plays an important role in the etiology of most of the neuroinflammatory disorders. To prevent long-term dysfunction inflammation in the central nervous system must be modulated with neuroprotective agents such as nonsteroidal anti-inflammatory drugs, steroids, phenolic thiazoles, nitrones, catechins, nitric oxide synthetase inhibitors, flavonoids, and phosphodiesterase inhibitors. Few drugs are found to be effective and their therapeutic benefit is hampered by side effects. Most of the neuroprotective agents are free radical scavengers and many inhibit only one or two aspects of inflammation. The complement inhibitory activity of most of these agents is either unknown or not established. Thus, there is doubt regarding their therapeutic value in most of the inflammatory disorders in which complement plays a major role. In this context the role of a multifunctional protein, vaccinia virus complement control protein (VCP), is quite significant as it may play a pivotal role in the treatment of several neuroinflammatory disorders. VCP is known to inhibit both complement pathways involved in inflammation. It is also known to inhibit cytokines and chemokines in inflammation. Our recent studies on rats demonstrate that VCP administration inhibits macrophage infiltration, reduces spinal cord destruction, and improves motor skills associated with spinal cord injury, establishing VCP as a strong candidate for neuroprotection. Thus, complement inhibitors such as VCP can serve as neuroprotective agents in inflammation associated with several neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15681806     DOI: 10.1196/annals.1332.010

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  10 in total

Review 1.  Viral-derived complement inhibitors: current status and potential role in immunomodulation.

Authors:  Hadi Abou-El-Hassan; Hassan Zaraket
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-26

2.  Complement C3 Inhibition Modulates Neurodegeneration in Chronic Traumatic Brain Injury.

Authors:  Mary Ellene Boulos; Michael Johnathan Charles Bray
Journal:  J Neurosci       Date:  2018-08-15       Impact factor: 6.167

Review 3.  Association between leukotriene-modifying agents and suicide: what is the evidence?

Authors:  Glen T Schumock; Todd A Lee; Min J Joo; Robert J Valuck; Leslie T Stayner; Robert D Gibbons
Journal:  Drug Saf       Date:  2011-07-01       Impact factor: 5.606

4.  Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma.

Authors:  Cigall Kadoch; Jing Li; Valerie S Wong; Lingjing Chen; Soonmee Cha; Pamela Munster; Clifford A Lowell; Marc A Shuman; James L Rubenstein
Journal:  Clin Cancer Res       Date:  2013-11-04       Impact factor: 12.531

5.  Another barrier to regeneration in the CNS: activated macrophages induce extensive retraction of dystrophic axons through direct physical interactions.

Authors:  Kevin P Horn; Sarah A Busch; Alicia L Hawthorne; Nico van Rooijen; Jerry Silver
Journal:  J Neurosci       Date:  2008-09-17       Impact factor: 6.167

6.  Immunity and inflammation in neurodegenerative diseases.

Authors:  Giuseppe Cappellano; Miryam Carecchio; Thomas Fleetwood; Luca Magistrelli; Roberto Cantello; Umberto Dianzani; Cristoforo Comi
Journal:  Am J Neurodegener Dis       Date:  2013-06-21

7.  Neuroprotective effects of flavonoids on hypoxia-, glutamate-, and oxidative stress-induced retinal ganglion cell death.

Authors:  Mao Nakayama; Makoto Aihara; Yi-Ning Chen; Makoto Araie; Kaori Tomita-Yokotani; Tsukasa Iwashina
Journal:  Mol Vis       Date:  2011-07-02       Impact factor: 2.367

8.  Resveratrol post-transcriptionally regulates pro-inflammatory gene expression via regulation of KSRP RNA binding activity.

Authors:  Franziska Bollmann; Julia Art; Jenny Henke; Katharina Schrick; Verena Besche; Matthias Bros; Huige Li; Daniel Siuda; Norbert Handler; Florian Bauer; Thomas Erker; Felix Behnke; Bettina Mönch; Lorena Härdle; Markus Hoffmann; Ching-Yi Chen; Ulrich Förstermann; Verena M Dirsch; Oliver Werz; Hartmut Kleinert; Andrea Pautz
Journal:  Nucleic Acids Res       Date:  2014-10-28       Impact factor: 16.971

9.  Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice.

Authors:  Iris Leinhase; Michal Rozanski; Denise Harhausen; Joshua M Thurman; Oliver I Schmidt; Amir M Hossini; Mohy E Taha; Daniel Rittirsch; Peter A Ward; V Michael Holers; Wolfgang Ertel; Philip F Stahel
Journal:  J Neuroinflammation       Date:  2007-05-02       Impact factor: 8.322

10.  Temporal gene profiling of the 5XFAD transgenic mouse model highlights the importance of microglial activation in Alzheimer's disease.

Authors:  Véréna Landel; Kévin Baranger; Isabelle Virard; Béatrice Loriod; Michel Khrestchatisky; Santiago Rivera; Philippe Benech; François Féron
Journal:  Mol Neurodegener       Date:  2014-09-11       Impact factor: 14.195

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.